CFDE Data Portal | Search MAFA-AS1

	Label	Description
	MAFA-AS1 Gene (Entity type)	ENSG00000254338 - MAFA antisense RNA 1
	GSE226285 3 V 0 GLUTATHIONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE152441,GSE152442 6 V 4 FOLIC ACID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE109285 3 V 2 GLUCAGON MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE128240 0 V 1 CYCLOPHOSPHAMIDE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE119978 GSE180930 cisplatin 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216273 GSE216292 palbociclib 0 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE184210 0 V 1 GLUCAGON MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE119369 H10 inhibition 1 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE196035 GSE196037 MEN1 inhibition 6 v 10 human up Gene Set (Entity type)	A Gene Set from LINCS

MAFA-AS1

ENSG00000254338 - MAFA antisense RNA 1

GSE226285 3 V 0 GLUTATHIONE HUMAN UP

A Gene Set from LINCS

GSE152441,GSE152442 6 V 4 FOLIC ACID HUMAN UP

A Gene Set from LINCS

GSE109285 3 V 2 GLUCAGON MOUSE UP

A Gene Set from LINCS

GSE128240 0 V 1 CYCLOPHOSPHAMIDE MOUSE UP

A Gene Set from LINCS

GSE119978 GSE180930 cisplatin 3 v 1 human dn

A Gene Set from LINCS

GSE216273 GSE216292 palbociclib 0 v 7 human up

A Gene Set from LINCS

GSE184210 0 V 1 GLUCAGON MOUSE DN

A Gene Set from LINCS

GSE119369 H10 inhibition 1 v 5 human up

A Gene Set from LINCS

GSE196035 GSE196037 MEN1 inhibition 6 v 10 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.